Stock Price & Volume | Full Chart
30-Day Implied Volatility | IV30 Full Chart
No headlines found.
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
Globe Newswire (Thu, 16-Mar 8:00 AM ET)
Aprea Therapeutics to Present at Oppenheimer's 33rd Annual Healthcare Conference
Globe Newswire (Tue, 7-Mar 8:00 AM ET)
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Globe Newswire (Wed, 1-Mar 4:05 PM ET)
Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
Globe Newswire (Mon, 27-Feb 4:05 PM ET)
Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
Globe Newswire (Wed, 22-Feb 8:41 PM ET)
Aprea Therapeutics Announces Proposed Public Offering of Common Stock
Globe Newswire (Wed, 22-Feb 4:05 PM ET)
Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI)
Globe Newswire (Wed, 15-Feb 8:00 AM ET)
Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split
Globe Newswire (Mon, 13-Feb 7:00 AM ET)
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer
Globe Newswire (Mon, 30-Jan 8:00 AM ET)
Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit
Globe Newswire (Thu, 19-Jan 8:00 AM ET)
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).
Aprea Therapeutics trades on the NASDAQ stock market under the symbol APRE.
As of March 22, 2023, APRE stock price declined to $4.82 with 16,219 million shares trading.
APRE has a beta of 0.97, meaning it tends to be less sensitive to market movements. APRE has a correlation of 0.03 to the broad based SPY ETF.
APRE has a market cap of $17.99 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, APRE stock traded as high as $822.30 and as low as $.47.
The top ETF exchange traded funds that APRE belongs to (by Net Assets): VXF, VTI, ITOT.
APRE has underperformed the market in the last year with a price return of -86.8% while the SPY ETF lost -11.3%. APRE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -32.5% and -2.2%, respectively, while the SPY returned +3.4% and -1.3%, respectively.
APRE support price is $4.71 and resistance is $5.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APRE stock will trade within this expected range on the day.